News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Capital return
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bioventus Inc. (BVS) reported strong Q2 2026 results with a significant jump in net income and reaffirmed its full-year 2026 sales guidance of US$600 million to US$610 million. The company's investment narrative focuses on converting modest sales growth into higher profitability while managing debt. …
Bioventus (BVS) stock surged 13.7% following a strong Q2 earnings report, showcasing adjusted EBITDA of US$35 million on US$153.2 million revenue and healthy cash generation. While the company's profitability and cash flow are positive, concerns remain regarding its reliance on a narrow product set, …
Bioventus Inc. reported strong second-quarter 2026 financial results, with reported revenue increasing 4% to $153.2 million and GAAP earnings per diluted share rising significantly to $0.47. The company reaffirmed its full-year 2026 guidance for revenue, Adjusted Diluted EPS, and cash from operations, and announced …
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's offering documents and public …
Bioventus Inc. reported strong second-quarter 2026 financial results, with reported revenue increasing 4% to $153.2 million and GAAP earnings per diluted share rising significantly to $0.47. The company reaffirmed its full-year 2026 guidance for revenue, Adjusted Diluted EPS, and cash from operations, and announced …
Bioventus Inc. (Nasdaq: BVS) reported a significant surge in Q2 2026 net income to $33.4 million, up from $7.5 million year-over-year, driven by strong net sales of $153.2 million and the removal of a deferred tax asset valuation allowance. The company reaffirmed its full-year …
This article identifies five growth stocks that align with Peter Lynch's investment philosophy, combining valuation discipline with strong financial health and growth prospects. It explains a screening methodology using the P/E ratio, Piotroski F-score, and five-year earnings growth rate to find companies like National …
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's initial public offering documents …
Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Bioventus made materially false …
Wall Street expects a year-over-year increase in earnings on higher revenues when Bioventus (BVS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …
BlackRock, Inc. has disclosed a passive ownership stake of 5.02% in Bioventus Inc.'s Class A stock, totaling 3,404,523 shares. This information was reported via a Schedule 13G filing, indicating BlackRock holds sole voting power over 3,350,552 shares and sole dispositive power over all 3,404,523 …
Search by ticker symbol or company name and select a result to open its chart.